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Abstract
Background: Microarrays permit biologists to simultaneously measure the mRNA abundance of
thousands of genes. An important issue facing investigators planning microarray experiments is how
to estimate the sample size required for good statistical power. What is the projected sample size
or number of replicate chips needed to address the multiple hypotheses with acceptable accuracy?
Statistical methods exist for calculating power based upon a single hypothesis, using estimates of
the variability in data from pilot studies. There is, however, a need for methods to estimate power
and/or required sample sizes in situations where multiple hypotheses are being tested, such as in
microarray experiments. In addition, investigators frequently do not have pilot data to estimate the
sample sizes required for microarray studies.
Results: To address this challenge, we have developed a Microrarray PowerAtlas [1]. The atlas
enables estimation of statistical power by allowing investigators to appropriately plan studies by
building upon previous studies that have similar experimental characteristics. Currently, there are
sample sizes and power estimates based on 632 experiments from Gene Expression Omnibus
(GEO). The PowerAtlas also permits investigators to upload their own pilot data and derive power
and sample size estimates from these data. This resource will be updated regularly with new
datasets from GEO and other databases such as The Nottingham Arabidopsis Stock Center
(NASC).
Conclusion: This resource provides a valuable tool for investigators who are planning efficient
microarray studies and estimating required sample sizes.
Background
Planning microarray studies provides unique challenges
to investigators with respect to estimating power and the
sample size required for a study. The questions proposed
may be quite general and exploratory, such as "which
genes are differentially expressed in response to a given
treatment?" A microarray study should have a high prob-
ability to answer, at least in part, the questions and
hypotheses being proposed [loosely speaking, power or in
our case Expected Discovery Rate (EDR)]. It should also
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have a high probability that those genes declared signifi-
cant are truly differentially expressed (i.e. the 'True Posi-
tive' probability should be high). Sample size is a critical
determinant of statistical power and expected error rates.
In traditional biomedical studies, investigators test one or
at most a few hypotheses. This is not the case in microar-
ray studies. Each treatment or group comparison involves
the testing of every gene on the chip, which may number
in the 10,000's. Some microarray experiments may
involve multiple groups; thus the total number of hypoth-
eses tested in a microarray experiment can run in the
100,000 s or more. In addition, the effects size and vari-
ance for each hypothesis may be different; resulting in dif-
ferent power estimates for each and every gene by
treatment comparison.
Some investigators have proposed approaches to estimat-
ing required sample size for microarray research [2-4], but
most of these methods calculate power based upon an
arbitrary level of change being biologically relevant and
constant across all genes. These methods do not take into
account the amount of variability in each gene nor specify
a hypothesized distribution of effect sizes, and do not
incorporate some of the recently developed approaches to
account for multiple testing in high-dimensional biol-
ogy(HDB) [5].
Calculating required sample sizes for a study requires an
estimate of the variability in the dependent variable, in
the case of microarray studies the genes' expression levels.
This information is frequently derived from previous pilot
studies performed by the research team or from similar
data in the literature. Integrating information from pilot
studies that illustrate the variability of all the genes in a
study provides empirically driven and theoretically defen-
sible sample size estimates. We have formalized such an
approach [5]. Rather than using traditional power (1-β)
we introduced the concept of Expected Discovery Rate
(EDR). EDR is the average power (see table 1 for a defini-
tion of A, B, C, and D) for all genes for which the null
hypothesis is false in an experiment. EDR is the E [Q]
where Q = D/(D+B) if D+B>0 and Q = 0 otherwise and
can be interpreted as the expected proportion of genes
that are truly differentially expressed that will be declared
to be differentially expressed. Microarray studies are
affected by multiple testing issues; thus, when considering
power studies one must not only consider the alpha (sig-
nificance) level cut-off used, but also the expected propor-
tion of genes that are True Positives (PTP), which is
similar in concept to the False Discovery Rate. The PTP
may be defined as (again A, B, C and D are defined in table
1) the E [R] where R = D/(C+D) if C+D>0 and R = 0 oth-
erwise. The PTP is the expected proportion of genes that
For the GDS486 dataset [18] the EDR is presented across a  variety of sample sizes and alpha levels Figure 2
For the GDS486 dataset [18] the EDR is presented across a 
variety of sample sizes and alpha levels.
Table 1: Quantities of interest in microarray experiments
Genes for which there is not a 
real effect
Genes for which there is not a 
real effect
Genes not declared significant at designated thereshold A B
Genes declared significant at designated thereshold C D
Estimated PTP, PTN, and EDR for the GDS486 [17] dataset  for a variety of samples sizes at an alpha level of 0.05 Figure 1
Estimated PTP, PTN, and EDR for the GDS486 [17] dataset 
for a variety of samples sizes at an alpha level of 0.05.BMC Bioinformatics 2006, 7:84 http://www.biomedcentral.com/1471-2105/7/84
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are declared significantly differentially expressed between
the two samples that are actually differentially expressed
between the two populations. A higher value for PTP is
considered more desirable. The software also provides the
Probability of a True Negative (PTN), which is the expected
proportion of genes that are not declared significantly dif-
ferentially expressed between the two samples that are
actually not differentially expressed between the two pop-
ulations. The use of EDR, PTP, and α provides a coherent
way to estimate the sample size required for microarray
research that is consistent with current approaches to ana-
lyzing microarray data and conceptualizing the process of
massive multiple hypothesis testing in HDB research
[6,7]. The PowerAtlas implements the methods developed
by Gadbury et al [5] and adds further functionality.
The PowerAtlas works in two ways. Firstly, investigators
may upload their own pilot data and extrapolate out the
EDR, PTN, and PTP for a variety of sample sizes and α
(type 1 error rate) level combinations. Secondly, many
investigators do not have the opportunity to conduct their
own pilot microarray study, but this need not stop an
investigator. Given that many journals now require
authors to place microarray data in public databases [8]
before publication, investigators may draw upon these
public data as pilot information. We have developed the
PowerAtlas to assist investigators in the use of these public
data to estimate the sample sizes required for well-pow-
ered studies. We have downloaded all data from Gene
Expression Omnibus [9], reanalyzed it, and processed it
with the methods developed in Gadbury et al [5]. There-
For the GDS75 dataset [22] the PTP is presented across a  variety of sample sizes and alpha levels Figure 6
For the GDS75 dataset [22] the PTP is presented across a 
variety of sample sizes and alpha levels.
Estimated PTP, PTN, and EDR for the GDS75 [20] dataset  for a variety of samples sizes at an alpha level of 0.05 Figure 4
Estimated PTP, PTN, and EDR for the GDS75 [20] dataset 
for a variety of samples sizes at an alpha level of 0.05.
For the GDS486 dataset [19] the PTP is presented across a  variety of sample sizes and alpha levels Figure 3
For the GDS486 dataset [19] the PTP is presented across a 
variety of sample sizes and alpha levels.
For the GDS75 dataset [21] the EDR is presented across a  variety of sample sizes and alpha levels Figure 5
For the GDS75 dataset [21] the EDR is presented across a 
variety of sample sizes and alpha levels.BMC Bioinformatics 2006, 7:84 http://www.biomedcentral.com/1471-2105/7/84
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after, we have put the power and sample size calculations
for many of the datasets into a readily accessible and
searchable database [1]. It should be stressed that no one
study is a perfect replicate of the study an investigator
wishes to conduct, but similar studies can give a sense of
the plausible ranges of sample sizes. We recommend that
investigators examine several related experiments to get a
sense of the sample size required for robust EDR and high
PTP.
Designing a microarray study with the appropriate
number of replicates is cost efficient. The use of the Power-
Atlas will not only prevent investigators from using too
many samples in a group, resulting in wasted money; but
will also limit wasting money on experiments that have
too few replicates to have sufficient power to yield good
results.
Usage of the PowerAtlas
No registration is required to use the PowerAtlas, nor are
any programs or applets pushed to an investigator's com-
puter. An investigator simply accesses the PowerAtlas [1]
and selects the appropriate link to use public data or the
investigator's study-specific data.
The data in the PowerAtlas are taken directly from GEO. As
long as it meets the requirements outlined in 'Using Exist-
ing Public Data' the data is included in the PowerAtlas.
However, the data in GEO can be quite variable, due to
any number of reasons, including, but not limited to, the
image processing algorithm, normalization, and inferen-
tial statistical procedure used in the analysis. Thus when
using public data as a basis for planning future studies, an
investigator should consider the results from several data-
sets, consult the primary sources (GEO GDS files and jour-
nal publications of the data), and have a reasonable
understanding of the idiosyncrasies and applicability of
each dataset to the proposed experiment before using the
data. In addition, since each lab processes and handles
samples and runs microarrays slightly differently, when
possible, estimates of power should be based upon an
investigator's own pilot data, which will be more accurate
More realistic representation of the distribution of p-values  under the null hypothesis (no difference in gene expression  between the two groups) for a valid test Figure 8
More realistic representation of the distribution of p-values 
under the null hypothesis (no difference in gene expression 
between the two groups) for a valid test. The dotted Blue 
line is the expected distribution of p-values if the treatment 
has no effect and the solid Green line is the mixed-model 
[23] fit of the p-value constrained to be monotonically non-
decreasing.
Table 3: Estimated EDR and PTP for sample size of 7 per group at alpha levels of 0.05 and 0.001 extrapolated from a sample size of 3 
(row 2) from the PKD data and the estimated EDR and PTP group at alpha levels of 0.05 and 0.001 calculated in the follow up study of 
7 mice per group.
Estimated EDR for SS 7
 at α = 0.05
Estimated PTP for SS 7
 at α = 0.05
Estimated EDR for SS 7
 at α = 0.001
Estimated PTP for SS 7
 at α = 0.001
Pilot of 3 per group 0.415009 0.809616 0.119791 0.985287
Experiment of 7 per group 0.538771 0.772419 0.133711 0.976347
Idealized representation of the distribution of p-values under  the null hypothesis (no difference in gene expression  between the two groups) for a valid test Figure 7
Idealized representation of the distribution of p-values under 
the null hypothesis (no difference in gene expression 
between the two groups) for a valid test. The dotted Blue 
line is the expected distribution of p-values if the treatment 
has no effect and the solid Green line is the mixed-model 
[23] fit of the p-value constrained to be monotonically non-
decreasing.BMC Bioinformatics 2006, 7:84 http://www.biomedcentral.com/1471-2105/7/84
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for an investigator's future experimental power than will
extrapolations from other investigators' data.
Using the investigators' own data
To use the PowerAtlas with an investigator's own data a list
of p-values generated using a valid statistical method must
be available. Currently the PowerAtlas generates sample
sizes for two group comparisons only for any valid statis-
tical test [10]. Then use the following instructions:
• The investigator must possess/generate a tab delimited
file with one p-value per gene/feature for the main
hypothesis of interest with each p-value located on its
own line. There should be no identifiers for genes. All p-
values from all genes on a chip/array should be included.
• The file with p-values is uploaded to the web site.
• The investigator then enters the sample sizes (N1 and
N2) for each of the groups used to calculate the p-values.
• The investigator then may either use default or custom
settings for the sample sizes, significance (α) thresholds,
and number of iterations for the bootstrap to be used for
estimating power.
• The investigator selects submit. For a sense of runtime,
from an initial set of 12,500 p-values with EDR, PTP, and
PTN being calculated for 14 sample sizes and six thresh-
olds, the analysis takes 3–10 minutes.
• The investigator then will obtain a series of figures that
illustrate the EDR, PTP, and PTN for a variety of sample
sizes and significance (α) thresholds(examples are shown
in figures 1, 2, 3 for an Affymetrix dataset [11] and figures
4, 5, 6 for a cDNA experiment [12]). The investigator may
then choose the sample size and α level combination that
achieves the desired levels for EDR, PTP, and PTN.
Using existing public data
We have downloaded and processed all data that was in
GEO's ftp site as of Oct 1, 2004 into the PowerAtlas. One
type of information GEO allows to be entered is the group
to which a chip belongs. We conducted a pooled variance
t-test on all possible two-group intraGDS (GDS is the
GEO definition of an experiment) comparisons from all
datasets within GEO. During analysis some datasets were
removed. Reasons for removal include: A) The data per
chip was incomplete, for example, due to masking or
selecting genes based on present or absent calls. B) The p-
values did not follow the expected possible distributions
(monotonically non-decreasing from 0 to 1). Figure 7 and
8 illustrate a null data set (no more genes are significant
than are expected at random). Figure 9 illustrates a typical
p-value distribution for a good dataset for which the null
is false for some, but not all genes. Figures 10, 11, 12 rep-
resent distributions of p-values seen while processing
GEO that do not fit the expected distributions and thus
would be listed as NA. C) Only two group fully rand-
omized cDNA experiments can be analyzed, which pre-
vents some cDNA experiments, including all loop designs
and those that involve dye swaps unless in a balanced
Distribution of p-values for a dataset in GEO that does not  follow one of the possible distributions for p-values Figure 10
Distribution of p-values for a dataset in GEO that does not 
follow one of the possible distributions for p-values The dot-
ted Blue line is the expected distribution of p-values if the 
treatment has no effect and the solid Green line is the 
mixed-model [23] fit of the p-value constrained to be monot-
onically non-decreasing.
Distribution of p-values when there is a difference in the  gene expression between the two groups for some of the  genes, but not all of the genes Figure 9
Distribution of p-values when there is a difference in the 
gene expression between the two groups for some of the 
genes, but not all of the genes. This distribution is monotoni-
cally non-increasing from 0 to 1. The dotted Blue line is the 
expected distribution of p-values if the treatment has no 
effect and the solid Green line is the mixed-model [23] fit of 
the p-value constrained to be monotonically non-decreasing.BMC Bioinformatics 2006, 7:84 http://www.biomedcentral.com/1471-2105/7/84
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block design from being analyzed. [13-15]. D) Datasets
having fewer than two experimental groups and three
chips per group are also excluded.
To use the public data for estimating sample size:
• From the PowerAtlas web page an investigator selects the
option of using existing public data.
• The investigator makes a selection of desired chip type
(one or two channel) and the species of interest. At most,
one of each chip type or species of interest may be
selected. Alternatively, the investigator may also select
only a chip type or a species.
• A list of all experiments will appear that meet the selec-
tion criteria. The number of datasets can range from 0
(most bacteria on single channel chips) to more 200 for
Human and Mouse on single channel chips (see table 2).
• The investigator can read a brief description, taken
directly from GEO, of all the experiments and find those
that are most similar to their proposed experiment(s).
• The investigator then selects the checkbox to the left of
the desired datasets and press Submit to get additional
information.
• The investigator receives a report with a link to the GEO
description should additional information be needed.
• There are also links to a printable HTML report that
includes a description of the dataset, the EDR, PTP, and
PTN (figures 1 and 4) at an α level of 0.05 as well as a
description of how to interpret the results.
• In datasets with more than 2 groups the two groups with
the largest sample sizes are given in the HTML report.
There is a link to jpeg images for the other IntraGDS com-
parisons in the data set. In addition there is a link to a
downloadable zip file that contains graphs illustrating the
EDR (figures 2 and 5), PTP (figures 3 and 6), and PTN for
a variety of α and sample sizes in a directory structure for
each two group comparison. There is also an Excel file
provided that contains the numbers underlying the fig-
ures.
Illustrative example of the accuracy and utility of the 
PowerAtlas
We provide a concrete example for illustrative purposes.
In one study (unpublished) the RNA kidneys from indi-
vidual mice that were homozygous for a PKDPH muta-
tion were collected. Mice were selected from a F2 cross
that had a very high kidney length to width ratio (three
mice) or a very low length to width ratio (three mice). This
measure is one determinant of polycystic kidney disease
severity. The RNA was run on the Affymetrix Mu74Av2
array and processed with MAS 5.0 (Affymetrix, Inc, Emor-
yville, CA). Figure 13 illustrates the distribution of p-val-
Distribution of p-values for a dataset in GEO that does not  follow one of the possible distributions for p-values Figure 11
Distribution of p-values for a dataset in GEO that does not 
follow one of the possible distributions for p-values. The dot-
ted Blue line is the expected distribution of p-values if the 
treatment has no effect and the solid Green line is the 
mixed-model [23] fit of the p-value constrained to be monot-
onically non-decreasing. The dotted Blue line is the expected 
distribution of p-values if the treatment has no effect and the 
solid Green line is the mixed-model [23] fit of the p-value 
constrained to be monotonically non-decreasing.
Distribution of p-values for a dataset in GEO that does not  follow one of the possible distributions for p-values Figure 12
Distribution of p-values for a dataset in GEO that does not 
follow one of the possible distributions for p-values. The dot-
ted Blue line is the expected distribution of p-values if the 
treatment has no effect and the solid Green line is the 
mixed-model [23] fit of the p-value constrained to be monot-
onically non-decreasing.BMC Bioinformatics 2006, 7:84 http://www.biomedcentral.com/1471-2105/7/84
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ues for the 2-group comparison of the gene expression
levels between the high and low kidney length-to-width
ratio mice. These p-values were run through the PowerAt-
las. We selected a target sample size of seven per group to
have an EDR of > 40% and PTP > 80% at α<0.05. An addi-
tional seven mice were run from each extreme of the kid-
ney length-to-width ratio distribution. The distribution of
the p-values for the seven mice per group comparison is
given in figure 14. Table 3 illustrates the EDR and PTP at
α = 0.05 and 0.0001 for a sample size of seven per group
that were estimated from the initial sample of three per
group (row 2). These numbers are compared to the actual
EDR and PTP that were calculated at α = 0.05 and 0.0001
for the follow on study at a sample size of seven per group
(row 3). The numbers are remarkably similar.
Conclusion
The PowerAtlas provides investigators the option of using
their own pilot data or drawing from a public domain
microarray data sets to calculate sample sizes and statisti-
cal power for a proposed study. The overall goal is to esti-
mate the sample size required to be able to answer the
hypothesis of interest with a high EDR and a high PTP
without using too many chips. Once the graphs and tables
most appropriate are identified (which may involve exam-
ining several datasets), the investigator must decide upon
the sample size to pursue. Unlike single hypothesis-driven
research, a huge number of genes often are typically differ-
entially expressed in a single microarray experiment and a
study may yield many (often thousands) of significant
genes. It is generally difficult for a single laboratory to fol-
Table 2: Itemization of the number type and species of chips available. NA means power estimation is not available. See section "Using 
existing public data" for possible explanations why the datasets may have be listed as NA.
Dual Channel Dual Channel Single Channel Single Channel
Available NA Available NA
Arabidopsis thaliana 1 1 02 20
Aspergillus parasiticus 0100
Bacillus anthracis 0200
Bos taurus 0320
Caenorhabditis elegans 1210
Campylobacter jejuni 1100
Canis familiaris 0011
Capra hircus 0010
Chlamydomonas reinhardtii 1000
Cricetulus griseus 0100
Drosophila melanogaster 391 5 0
Drosophila simulans 2000
Drosophila yakuba 0200
Escherichia coli 5120
Escherichia coli K12 0010
Fundulus heteroclitus 0010
Homo sapiens 44 34 178 35
Marmota monax 0011
Mastomys natalensis 0001
Mus musculus 63 14 175 58
Mycobacterium tuberculosis 1000
Oncorhynchus mykiss 0400
Oryza sativa 0200
Pinus contorta 0010
Rattus norvegicus 6 8 68 13
Rhodobacter sphaeroides 0022
Saccharomyces cerevisiae 12 41 18 1
Saccharomyces pastorianus 0001
Saccharum sp. 0001
Salmo salar 0200
Salmonella enterica 1000
Sus scrofa 0110
Viruses 0001
Zea mays 1000
TOTAL 142 138 490 115BMC Bioinformatics 2006, 7:84 http://www.biomedcentral.com/1471-2105/7/84
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low-up or to investigate more than a few genes. Thus,
while an EDR of 80% or more may be in line with tradi-
tional power studies, investigators may not want or have
the laboratory resources to deal with large-scale high-
powered gene expression experiments where 1000 s of
genes are identified as differentially expressed. Thus, it
may be more appropriate to have a small list of genes in
which an investigator has high confidence that the genes
identified as differentially expressed are truly differentially
expressed. Thus, modest EDRs (10–40%) may be appro-
priate when conservative alphas are chosen to generate
high PTPs (80%+). On the other hand, when the investi-
gator wants to get a complete picture of the experimental
manipulations it may be more appropriate to use a liberal
alpha level (0.1) to have a high EDR, but this will yield a
lower PTP. Investigators should carefully consider what
error rate (the proportion of the genes that are studied fur-
ther that are false positives) is acceptable, how many
genes they can truly invest in studying, and how impor-
tant it is to have a complete list of differentially expressed
genes.
A few other issues should be considered when choosing
the sample size for an experiment. The first, one should
not rely upon any one study to drive the sample size. An
investigator should view several datasets to get an idea of
the range of possible sample sizes. Secondly, we have ana-
lyzed all the data in the PowerAtlas as if it were two groups
with fully randomized designs. This may not be the case;
experiments may be 2 or 3 way experiment with multiple
levels. If the actual experiment were these designs, the cal-
culated sample size may be an over estimate for the meth-
ods in the PowerAtlas  does not yet allow for using
information from other groups to estimate the variances
as methods such as ANOVA and linear models do. In
addition the hypothesis shown in the main graph may not
be the primary hypothesis of interest in a study, they are
simply the groups with the largest sample sizes, and the
other hypotheses should be reviewed as well. Investigators
should review the primary literature to verify what the true
experimental design was. We also assume the experiments
were conducted in a rigorous fashion and have not been
confounded by non-biological sources of error, which
may adversely effect power nor does the use of good sam-
ple size obviate the need for good experimental design
and conduct of the experiment [16].
Future directions
There are several areas where the functions of the PowerAt-
las will be expanded. First we will augment the data in the
database by revising the data from GEO every six months
and we will add data from additional sources such as the
Nottingham Arabidopsis Stock Center (NASC). In the PTP
graph at low n and small α, the lines of the PTP sometimes
cross, which is due to the fact under these conditions
sometimes very few or even zero genes are declared signif-
icant. As this is the denominator of PTP the PTP is 0. Until
the sample size gets large enough to declare enough genes
differentially expressed at a chosen (small) threshold, PTP
lines may cross over each other. We are working to elimi-
Distribution of p-values for the comparison of RNA from 3  murine with homozygous PKDH mutations and a high kidney  length-to-width ratio and RNA from 3 mice with  homozygous PKDH mutations and a low kidney length-to- width ratios Figure 13
Distribution of p-values for the comparison of RNA from 3 
murine with homozygous PKDH mutations and a high kidney 
length-to-width ratio and RNA from 3 mice with 
homozygous PKDH mutations and a low kidney length-to-
width ratios. The dotted Blue line is the expected distribu-
tion of p-values if the treatment has no effect and the solid 
Green line is the mixed-model [23] fit of the p-value con-
strained to be monotonically non-decreasing.
Distribution of p-values for the comparison of RNA from 7  mice with PKDH mutations and a high kidney length to width  ratio and RNA from 7 mice with PKDH mutations and a low  kidney length to width ratio Figure 14
Distribution of p-values for the comparison of RNA from 7 
mice with PKDH mutations and a high kidney length to width 
ratio and RNA from 7 mice with PKDH mutations and a low 
kidney length to width ratio. The dotted blue line is the 
expected distribution of p-values if the treatment has no 
effect and the solid green line is the mixed-model [23] fit of 
the p-value constrained to be monotonically non-decreasing.BMC Bioinformatics 2006, 7:84 http://www.biomedcentral.com/1471-2105/7/84
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nate this issue from our method. Currently, only point
estimates of the EDR, PTP and PTN are generated. Future
work will generate confidence intervals on these esti-
mates. We are also extending the power estimation proce-
dures to handle ANOVA and linear models, which will
allow for power estimation for loops designs, the correct
analysis of datasets with multiple groups, and time series
data. When these methods have been developed they will
be incorporated into the PowerAtlas.
Availability and requirements
• Project name: The PowerAtlas
•  Project home page: http://www.powerAtlas.org also
http://www.poweratlas.net 
• Operating system(s): Web-based application
• Programming language: Java
• Other requirements: Web browser. Unzip utility
• License: None
• Any restrictions to use by non-academics: None
Abbreviations
ANOVA: Analysis of Variance
EDR: Expected discovery rate
GDS: Gene Expression Omnibus Dataset
GEO: Gene Expression Omnibus
HDB: High Dimensional Biology
PTP: Probability of a True Positive
PTN: Probability of a True Negative
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